Active Biotech AB

Active Biotech AB (publ) is a biotechnology company based in Lund, Sweden, incorporated in 1983. It researches, develops, produces, markets, and sells medical, chemical, and biotechnology products in Sweden. The company is developing Tasquinimod, a small molecule immunomodulator in Phase II clinical trials for hematological malignancies; Laquinimod, an immunomodulator for severe inflammatory eye diseases such as non-infectious non-anterior uveitis; and Naptumomab estafenatox, a tumor-targeting immunotherapy for solid tumors. It collaborates with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas, Stichting Haemato-Oncologie Volwassenen Netherlands, Stanford Medicine, and the Global Ophthalmic Research Center.